Medtronic Drug-Coated Balloon Gets FDA Breakthrough Status

Medtronic’s drug-coated balloon has received FDA breakthrough status, according to MedTech Dive. The company plans to study the device in patients with peripheral artery disease below the knee.

MedTech Dive characterized peripheral artery disease below the knee as a historically difficult condition to treat. The reported designation places Medtronic’s planned study focus on a specific peripheral artery disease setting.

Planned study focus

Medtronic plans to study its drug-coated balloon in patients with peripheral artery disease below the knee, MedTech Dive reported. The publisher’s report identifies the below-the-knee population as the intended focus for the device study.

For medical device sales professionals, the development concerns a drug-coated balloon and Medtronic’s stated plan to evaluate it in the below-the-knee peripheral artery disease population. MedTech Dive’s report connects that study plan with the FDA breakthrough status.

Regulatory designation reported

MedTech Dive reported that the FDA granted breakthrough status to Medtronic’s drug-coated balloon. The report also noted Medtronic’s plan to study the device in a condition described as historically difficult to treat.

The event centers on the FDA breakthrough status and the planned study of the drug-coated balloon in patients with peripheral artery disease below the knee. MedTech Dive reported both the designation and the intended study population.

Industry relevance

The report provides a regulatory and clinical-study update involving Medtronic’s drug-coated balloon. Medical device sales professionals following peripheral artery disease technologies can note the reported FDA breakthrough status and Medtronic’s stated study plan.

As reported by MedTech Dive, the device is intended for study in below-the-knee peripheral artery disease, a treatment setting the publisher described as historically difficult. The available report does not provide further study details.